These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 33437903)

  • 1. The Natural History of NAFLD, a Community-Based Study at a Large Health Care Delivery System in the United States.
    Nyberg LM; Cheetham TC; Patton HM; Yang SJ; Chiang KM; Caparosa SL; Stern JA; Nyberg AH
    Hepatol Commun; 2021 Jan; 5(1):83-96. PubMed ID: 33437903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: a real world analysis of Medicare data.
    Loomba R; Wong R; Fraysse J; Shreay S; Li S; Harrison S; Gordon SC
    Aliment Pharmacol Ther; 2020 Jun; 51(11):1149-1159. PubMed ID: 32372515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study.
    Vilar-Gomez E; Calzadilla-Bertot L; Wai-Sun Wong V; Castellanos M; Aller-de la Fuente R; Metwally M; Eslam M; Gonzalez-Fabian L; Alvarez-Quiñones Sanz M; Conde-Martin AF; De Boer B; McLeod D; Hung Chan AW; Chalasani N; George J; Adams LA; Romero-Gomez M
    Gastroenterology; 2018 Aug; 155(2):443-457.e17. PubMed ID: 29733831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patterns and predictors of mortality and disease progression among patients with non-alcoholic fatty liver disease.
    Canbay A; Kachru N; Haas JS; Sowa JP; Meise D; Ozbay AB
    Aliment Pharmacol Ther; 2020 Oct; 52(7):1185-1194. PubMed ID: 33016540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Healthcare resource utilization and costs of nonalcoholic steatohepatitis patients with advanced liver disease in Italy.
    Petta S; Ting J; Saragoni S; Degli Esposti L; Shreay S; Petroni ML; Marchesini G;
    Nutr Metab Cardiovasc Dis; 2020 Jun; 30(6):1014-1022. PubMed ID: 32423665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data.
    Kabbany MN; Conjeevaram Selvakumar PK; Watt K; Lopez R; Akras Z; Zein N; Carey W; Alkhouri N
    Am J Gastroenterol; 2017 Apr; 112(4):581-587. PubMed ID: 28195177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diabetes impacts prediction of cirrhosis and prognosis by non-invasive fibrosis models in non-alcoholic fatty liver disease.
    Bertot LC; Jeffrey GP; de Boer B; MacQuillan G; Garas G; Chin J; Huang Y; Adams LA
    Liver Int; 2018 Oct; 38(10):1793-1802. PubMed ID: 29575516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical course of non-alcoholic fatty liver disease and the implications for clinical trial design.
    Allen AM; Therneau TM; Ahmed OT; Gidener T; Mara KC; Larson JJ; Canning RE; Benson JT; Kamath PS
    J Hepatol; 2022 Nov; 77(5):1237-1245. PubMed ID: 35843374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diabetes, Plasma Glucose, and Incidence of Fatty Liver, Cirrhosis, and Liver Cancer: A Prospective Study of 0.5 Million People.
    Pang Y; Kartsonaki C; Turnbull I; Guo Y; Clarke R; Chen Y; Bragg F; Yang L; Bian Z; Millwood IY; Hao J; Han X; Zang Y; Chen J; Li L; Holmes MV; Chen Z
    Hepatology; 2018 Oct; 68(4):1308-1318. PubMed ID: 29734463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: Implications for Liver Transplantation.
    Younossi ZM; Marchesini G; Pinto-Cortez H; Petta S
    Transplantation; 2019 Jan; 103(1):22-27. PubMed ID: 30335697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors for biopsy-proven advanced non-alcoholic fatty liver disease in the Veterans Health Administration.
    Patel YA; Gifford EJ; Glass LM; McNeil R; Turner MJ; Han B; Provenzale D; Choi SS; Moylan CA; Hunt CM
    Aliment Pharmacol Ther; 2018 Jan; 47(2):268-278. PubMed ID: 29115682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trends in hospitalizations for chronic liver disease-related liver failure in the United States, 2005-2014.
    Kim D; Cholankeril G; Li AA; Kim W; Tighe SP; Hameed B; Kwo PY; Harrison SA; Younossi ZM; Ahmed A
    Liver Int; 2019 Sep; 39(9):1661-1671. PubMed ID: 31081997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics and outcome of hepatocellular carcinoma in patients with NAFLD without cirrhosis.
    Bengtsson B; Stål P; Wahlin S; Björkström NK; Hagström H
    Liver Int; 2019 Jun; 39(6):1098-1108. PubMed ID: 30829446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Underrecognition and Suboptimal Quality of Care for Nonalcoholic Fatty Liver Disease Cirrhosis in Primary Care Patients with Diabetes Mellitus.
    Chu JN; Goldman ML; Brandman D; Sohn JH; Islam K; Ross LA; Fox RK
    Am J Med; 2024 Feb; 137(2):172-177.e2. PubMed ID: 37890572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonalcoholic fatty liver disease increases risk of incident advanced chronic kidney disease: a propensity-matched cohort study.
    Park H; Dawwas GK; Liu X; Nguyen MH
    J Intern Med; 2019 Dec; 286(6):711-722. PubMed ID: 31359543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease.
    Estes C; Razavi H; Loomba R; Younossi Z; Sanyal AJ
    Hepatology; 2018 Jan; 67(1):123-133. PubMed ID: 28802062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study.
    Bhala N; Angulo P; van der Poorten D; Lee E; Hui JM; Saracco G; Adams LA; Charatcharoenwitthaya P; Topping JH; Bugianesi E; Day CP; George J
    Hepatology; 2011 Oct; 54(4):1208-16. PubMed ID: 21688282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term outcomes of non-alcoholic fatty liver disease and the risk factors for mortality and hepatocellular carcinoma in a Japanese population.
    Kogiso T; Sagawa T; Kodama K; Taniai M; Hashimoto E; Tokushige K
    J Gastroenterol Hepatol; 2020 Sep; 35(9):1579-1589. PubMed ID: 31975453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of a Simulation Model to Estimate Long-term Outcomes in Patients with Nonalcoholic Fatty Liver Disease.
    Chhatwal J; Dalgic OO; Chen W; Samur S; Bethea ED; Xiao J; Hur C; Corey KE; Loomba R
    JAMA Netw Open; 2022 Sep; 5(9):e2230426. PubMed ID: 36098969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trends in Characteristics, Mortality, and Other Outcomes of Patients With Newly Diagnosed Cirrhosis.
    Orman ES; Roberts A; Ghabril M; Nephew L; Desai AP; Patidar K; Chalasani N
    JAMA Netw Open; 2019 Jun; 2(6):e196412. PubMed ID: 31251379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.